Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.63, $0.50 better than the analyst estimate of $1.13. Revenue for the quarter came in at $580 million versus the consensus estimate of $547.1 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.